Search

Displaying results 2781 - 2790 of 10000 in total
  1. Target

    Tumor necrosis factor receptor superfamily member 10B

    go.drugbank.com/bio_entities/BE0003433
    TargetHumans

    Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:10549288). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation wh...

    Polypeptides: Tumor necrosis factor receptor superfamily member 10B
  2. Target

    Tumor necrosis factor receptor superfamily member 10A

    go.drugbank.com/bio_entities/BE0010564
    TargetHumans

    Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:26457518, PubMed:38532423). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteoly...

    Polypeptides: Tumor necrosis factor receptor superfamily member 10A
  3. Drug

    Tenocyclidine

    go.drugbank.com/drugs/DB01520
    IllicitInvestigational

    It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.

  4. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.

  5. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

  6. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    It is a topically delivered small protein that acts as an anti-inflammatory agent.

  7. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.

    Synonyms: Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1, Immunoglobulin G1 [242-phenylalanine,243-glutamic acid,260-tyrosine,262-threonine,264-glutamic acid,339-serine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding
  8. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701] … It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector.

  9. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.

  10. Drug

    L-tartaric acid

    go.drugbank.com/drugs/DB09459
    Approved

    Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics, and is a dihydroxyl derivative ...

    Synonyms: (+)-L-tartaric acid, L-threaric acidMixtures: PURGYL % 11+% 12,5 ORAL ÇÖZELTİ, 200 ML, E-Z-gas 2 Granules